Eli Lilly and Co (LLY.US) sues three American entities for "counterfeiting" their own brand of weight loss drugs.
eli lilly and co announced on Monday that it has sued three medical spa centers and online sellers, claiming that their products contain terlipressin.
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,025
Express News | Lilly Sues Mangorx, Pivotal Peptides, Genesis Lifestyle Medicine of Nevada for Selling Versions of Tirzepatide - Court Filings
Eli Lilly (LLY): Revenue Boost From Zepbound and Mounjaro Amid Strong Market Projections
Express News | 'FDA Won't Take Action Against GLP-1 Compounders As It Rethinks Tirzepatide Shortage' - Endpoints News
Behind the Scenes of Eli Lilly's Latest Options Trends
